Objective: To evaluate the diagnostic significance of detecting cytokeratin 19 (CK19) mRNA by quantitative reverse transcription polymerase chain reaction (RT-PCR) in benign and malignant pleurai effusions. Methods: CKI9 mRNA was examined by quantitative RT-PCR and CKI9 was detected by Enzyme-linked immunoadsorbent assay (ELISA) in 32 patients with malignant pleural effusions and 35 patients with benign pleural effusions. Results: On the threshold of 200 copies/HI, the positive rate ofCKl9 mRNA in patients with malignant pleural effusions was 62.5%. The positive rates of CKI9 mRNA and CKI9 in the malignant pleural effusions were significantly higher than those in the benign group (P<0.01). Furthermore, the positive rate of CKI9 mRNA was higher than that of CKI9 in the malignant group (P<0.05). Conclusion: Detection of CK19 mRNA can be a promising diagnostic marker in differential diagnosis of benign and malignant pleural effusions.
INTRODUCTION
Malignant pleural effusions often result from malignant tumors transferring into pleural cavity. Detecting tumor cells by RT-PCR is thought to be one of the most effective methods to judge micrometastases of malignant tumors. It is well known that cytokeratin 19 (CKI9) is one of the most useful markers for diagnosis and management of tumor. CKI9 mRNA is expressed in nearly all the epithelial malignancies and may be widely employed as a molecular marker for assessing the circulating tumor burden and diagnosing micrometastasis. Sequential quantification of CK19 mRNA levels in blood may potentially indicate colorectal cancer patients response to treatment and help identify patients at high risk for metastasis (Wong et al., 2001) . Yuan et a1. (2002) revealed the presence of circulating CKl9-expressing cancer cells in the blood of patients with untreated early-stage cervical carcinomas. Lockett et al. (1998) had developed keratin-19, c-myc, prolactin inducible protein (PIP) RT-PCR based method to identify axillary lymph node metastases in patients with breast cancer and thought it appeared to be a readily available and highly sensitive method for detecting breast cancer micrometastases.
In our study, CKI9 mRNA was detected by quantitative RT-PCR and CK19 examined by ELISA in benign and malignant pleural effusions.
Our aim was to evaluate the value of quantitative CK 19 mRNA RT-PCR method in the diagnosis of malignant pleural effusions.
METHODS

Patient population
The study population consisted of 67 in-patients with pleural effusions at the Second Affiliated Hospital of College of Medicine, Zhejiang University from May 2001 to April 2003. Of 32 patients with malignant pleural effusions, 18 were male and 14 were female. Their ages were between 45 and 77. Their primary diseases were: lung cancer (23 cases), breast cancer (4 cases), gastric cancer (2 cases), liver cancer (1 case), colorectal cancer (1 case), and lymphoma (1 case). Ten malignant cases were confirmed by cytology and others were subjected to pathological examination (pleural biopsy or operation). Of 35 patients with benign pleural effusions, 24 were male and 11 were female. Their ages were between 26 and 82. Their primary diseases were: tuberculousis (21 cases), peumonia (7 cases), uremia (5 cases), congestive heart disease (2 cases). All benign cases were confirmed by pathological examination or clinical manifestation and outcome.
Detection of CK19 mRNA
Pleural fluid samplings were performed before patients were treated by any chemical drug. To reduce the false positive risk by contamination of epidermal cells in the skin, 10 ml of the second tube of pleural fluid was collected after 5 ml of pleural fluid was aspirated. Cells from pleural fluid sampiing were prepared by centrifugation at 1000 g for 10 minutes for two times. Total mRNA was isolated by Trizol reagent according to the procedure of the supplier (Gibco Inc., America). Approximately 2 p.g mRNA from each sample was subjected to reverse transcription using RT Kit (Promega Inc., America) for 2-4 h at 42 ~ then PCR amplification was performed in a quantitative thermal cycler (7700 Sequence Detector, Perkin-Elmer, America) and the copies of CK19 mRNA were detected.
Forward and reverse primes of CK19 were bought from Jiu Sheng Inc.of Shanghai. PCR condition: 30 s at 4 ~ 15 s at 62 ~ 15 s at 72 ~ for 30 cycles amplification, then extend at 72 ~ for 10 min. Above 200 copies of CK19 mRNA was thought of as positive. 13-actin as an internal control showed that all samples displayed detectable circulating cell RNA.
Detection of CKI9
CK19 in the pleural fluid was detected by ELISA Kit (Mega Diagnostics, Inc., America). Above 3.7 ng/ml of CKI9 was thought of as positive.
Statistical analysis
The data were analyzed by Fisher's exact test and Mann-Whitney U test. A value of P<0.05 was regarded as statistically significant.
RESULTS
Levels of CK19 mRNA in benign and malignant pleural effusions
Detected by quantitative RT-PCR, the levels of CK19 mRNA in malignant pleural effusions ranged from 15 copies/I.d to 1.73x 108 copies/~tl. Its P25 (Percentile 25) and P75 (Percentile 75) were 73 copies/~tl and 38725 copies/~l respectively. The levels of CK19 mRNA in benign pleural effusions ranged from 0 copies/~tl to 19520 copies/btl. Its P25 and P75 were 0 copies/lal and 160 copies/~tl respectively. By Mann-Whitney U test, the levels of CK19 mRNA were much higher in the malignant pleural effusions than in the benign group (P<0.01).
Comparison of positive rate of CK19 mRNA and CKI9 in pleurai effusions
Following our previous study, 200 copies/~l was selected as cut-off of CK19 mRNA by ROC curve analysis (Xu et al., 2003) . The positive rates of CKI9 mRNA in the group of malignant and benign pleural effusions were 62.5% (20/32) and 17.1% (3/35) respectively. By Fisher's exact text, there was significant difference between the two
